almagate has been researched along with Coronary Heart Disease in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Matthé, E; Sandner, D | 1 |
| Liew, G; Mitchell, P; Wong, TY | 1 |
2 other study(ies) available for almagate and Coronary Heart Disease
| Article | Year |
|---|---|
[Monotherapy of exudative age-related macular degeneration with ranibizumab in patients at cardiovascular risk. Advantages of ranibizumab compared to a combination with pegaptanib].
Topics: Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Aptamers, Nucleotide; Choroidal Neovascularization; Coronary Artery Bypass; Coronary Disease; Drug Therapy, Combination; Female; Humans; Intravitreal Injections; Male; Myocardial Infarction; Ranibizumab; Retrospective Studies; Risk Factors; Stents; Stroke; Treatment Outcome; Vascular Endothelial Growth Factor A; Visual Acuity; Wet Macular Degeneration | 2011 |
Clinical update: new treatments for age-related macular degeneration.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Aptamers, Nucleotide; Bevacizumab; Coronary Disease; Half-Life; Humans; Macular Degeneration; Randomized Controlled Trials as Topic; Ranibizumab; Treatment Outcome; Vascular Endothelial Growth Factor A | 2007 |